CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is $3.08B, above the global median of $1.15B
- PositionGross margin is 36%, higher than 95% of its Pharmaceutical Retailers peers (median 25.6%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.76%Above 5Y avg (2.65%)
Annual Rate
CNY 0.49Paid annual
Payout Ratio
57.5%Sustainable
Payback Period
36.0 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
20.72BCNY3.08B · vs all stocks (USD)
Trailing P/E
15.98xvs Pharmaceutical Retailers peers
Revenue (TTM)
27.52BCNY4.09B · vs all stocks (USD)
Profit Margin
4.67%vs Pharmaceutical Retailers peers
Beta
0.4120xvs all stocks
52-Week Change
2.72%vs all stocks
Market Capitalization
20.72BCNY3.08B · vs all stocks (USD)
Enterprise Value
19.76BCNY2.94B · vs all stocks (USD)
Trailing P/E
15.98xvs Pharmaceutical Retailers peers
Forward P/E
11.80xvs Pharmaceutical Retailers peers
PEG Ratio
1.28xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.7474xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
2.61xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.7180xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
8.45xvs Pharmaceutical Retailers peers
Gross Margin
36.05%vs Pharmaceutical Retailers peers
Profit Margin
4.67%vs Pharmaceutical Retailers peers
Operating Margin
10.52%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
4.84%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
15.77%vs Pharmaceutical Retailers peers
Revenue (TTM)
27.52BCNY4.09B · vs all stocks (USD)
Revenue per Share (TTM)
24.14CNYUpdated Aug 21, 2026Quarterly Revenue Growth
0.20%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
9.49BCNY1.41B · vs all stocks (USD)
EBITDA (TTM)
2.05BCNY304.67M · vs all stocks (USD)
Net Income (TTM)
1.29BCNY191.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.10%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
4.55BCNY676.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.32BCNY493.55M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4900CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.76%vs all stocks
5-Year Average Dividend Yield
2.65%vs all stocks
Payout Ratio
57.52%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
1.29BCNYFY2025 · Dec 31, 2025Revenue
27.50BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
18.06BCNYFY2025 · Dec 31, 2025Gross Profit
9.44BCNYFY2025 · Dec 31, 2025Operating Income
2.10BCNY311.58M · vs all stocks (USD)
Pre-tax Income
1.85BCNYFY2025 · Dec 31, 2025Income Tax Expense
490.53MCNYFY2025 · Dec 31, 2025Net Income
1.36BCNYFY2025 · Dec 31, 2025EBIT
1.93BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.56BCNYFY2025 · Dec 31, 2025Research & Development
41.27MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.34BCNYFY2025 · Dec 31, 2025Other Operating Expenses
138.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
69.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
77.34MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.08CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.08CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.14BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.14BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.36BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-123.67MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.07BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.62BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.91BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.36BCNYFY2025 · Dec 31, 2025Other Non-cash Items
437.49MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
304.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.12MCNYFY2025 · Dec 31, 2025Capital Expenditures
-455.49MCNYFY2025 · Dec 31, 2025Net Acquisitions
-93.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-683.17MCNYFY2025 · Dec 31, 2025Sale of Investments
263.85MCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.53MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-970.32MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
893.31MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.43BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-782.10MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.29BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.61BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.14BSharesUpdated Aug 21, 2026Float Shares
407.73MSharesUpdated Aug 21, 2026% Held by Insiders
65.23%vs all stocks
% Held by Institutions
13.55%vs all stocks
Total Cash (MRQ)
7.11BCNY1.06B · vs all stocks (USD)
Total Cash per Share (MRQ)
6.24CNYUpdated Aug 21, 2026Total Debt (MRQ)
5.17BCNY768.35M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5627xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
0.9270xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
6.91CNYUpdated Aug 21, 2026Total Assets
26.49BCNY3.94B · vs all stocks (USD)
Total Current Assets
13.38BCNYFY2025 · Dec 31, 2025Total Liabilities
17.83BCNYFY2025 · Dec 31, 2025Total Non-current Assets
13.11BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.76BCNYFY2025 · Dec 31, 2025Total Current Liabilities
15.07BCNYFY2025 · Dec 31, 2025Cash
3.88BCNYFY2025 · Dec 31, 2025Cash Equivalents
2.63BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.51BCNYFY2025 · Dec 31, 2025Other Short-term Investments
438.96MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.26BCNYFY2025 · Dec 31, 2025Inventory
4.14BCNYFY2025 · Dec 31, 2025Accounts Payable
9.94BCNYFY2025 · Dec 31, 2025Short-term Debt
2.81BCNYFY2025 · Dec 31, 2025Other Current Liabilities
30.00MCNYFY2025 · Dec 31, 2025Long-term Debt
2.69BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.14BCNYFY2025 · Dec 31, 2025Retained Earnings
4.31BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.66BCNY1.29B · vs all stocks (USD)
Treasury Stock
100.74MCNYFY2025 · Dec 31, 202552-Week Low
14.39CNYUpdated Aug 21, 202652-Week High
21.78CNYUpdated Aug 21, 202652-Week Change
2.72%vs all stocks
Beta
0.4120xvs all stocks
50-Day MA
17.60CNYUpdated Aug 21, 2026200-Day MA
18.14CNYUpdated Aug 21, 2026Avg 10-Day Volume
9.47MSharesUpdated Aug 21, 2026Avg 30-Day Volume
9.84MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.13CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 36%, higher than 95% of its Pharmaceutical Retailers peers (median 25.6%)Significant
Gross margin: 0.36Industry median: 0.26Industry P95: 0.36Peers compared: 29.00
Operating margin is 10.5%, higher than 95% of its Pharmaceutical Retailers peers (median 4.8%)Significant
Operating margin: 0.11Industry median: 0.05Industry P95: 0.08Peers compared: 29.00
Financial Health
Altman Z-Score 2.13: grey zoneSignificant
Altman Z-Score: 2.13
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Market cap is $3.08B, above the global median of $1.15BNotable
Market cap (USD): 3,080,641,222.504Global Median: 1,146,734,693.424
Revenue is $4.09B, above the global median of $520.53MNotable
Revenue (USD): 4,092,414,837.412Global Median: 520,528,949.311
Levered free cash flow is $493.55M, above the global median of $16.24MNotable
Levered free cash flow (USD): 493,554,870.543Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Sheng Siong Group Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Academy Sports and Outdoors, Inc.
Tier 1FlowUnit ReplicationInterfaceAttention
Sonic Automotive Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Aldrees Petroleum and Transport Services Company
Tier 1FlowUnit ReplicationInterfaceProduction
Metro Brands Ltd.
Tier 1FlowUnit ReplicationRiskInterface
Sumber Alfaria Trijaya Tbk
Tier 1FlowUnit ReplicationInterfaceProduction
Ocado Group Plc
Tier 1FlowUnit ReplicationInterfaceProduction
Topsports International Holdings Limited
Tier 1FlowUnit ReplicationRiskInterface
Zhongsheng Group Holdings Limited
Tier 1FlowUnit ReplicationInterfaceRisk
Cosmos Pharmaceutical Corp.
Tier 1FlowUnit ReplicationProductionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing Balance Medical Technology Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Vedant Fashions Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Polyus PJSC
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated